Buy TB500 (Thymosin B4 Acetate) in the UK
The 17-amino-acid actin-binding fragment of thymosin β-4, built around the LKKTETQ motif. Available in 10 mg lyophilised vials, HPLC-verified, COA-backed, with same-day dispatch and 24-hour delivery across the UK.
- HPLC-verified purity, lot-level COA
- Same-day dispatch before 4 PM London time
- 24-hour delivery to London, Manchester, Birmingham, Glasgow
- 24–48 hours to Sheffield, RAK, Liverpool
- Crypto or Card via Whop UK-wide
- Free shipping over £100
What TB-500 is
TB-500 is a synthetic 17-amino-acid fragment of thymosin β-4, a 43-residue actin-binding protein found throughout most mammalian tissues. TB-500 corresponds to the bioactive central region of the parent protein and is built around the LKKTETQ actin-binding motif — the functional core the fragment carries forward from the full molecule.
The mechanism is distinct from most other research peptides: TB-500 acts via actin sequestration, modulating the cytoskeleton to enable cell migration to injury sites. This is fundamentally different from BPC-157's angiogenesis pathway — which is why the two are often paired in research protocols. Full comparison in our BPC-157 vs TB-500 article.
What the research documents
Cardiac repair. Smart et al. 2007 (Nature) — thymosin β-4 mobilised adult epicardial progenitor cells and drove neovascularisation after myocardial infarction in mice. The highest-impact paper in the TB-4 literature.
Corneal wound healing. Sosne et al. published a series (2002 onwards) on accelerated corneal epithelial closure.
Dermal wound closure. Documented in rat full-thickness wound models.
Vial in UK inventory
UK delivery to your region
Buy TB-500 UK — FAQ
REVIVE LAB UK supplies TB-500 across all seven regions. Same-day dispatch, 24h delivery, Crypto/Whop available.
10 mg lyophilised, HPLC-verified, COA on every parcel.
Mechanism-wise yes — different pathways. Frequently paired in research protocols. No peer-reviewed stacking trial exists.
No published RCT for the fragment. Parent thymosin β-4 has some early-phase work.